Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 109

Results For "clinic"

3637 News Found

FUJIFILM India unveils FW500, advancing biochemistry innovation in diagnostics
News | October 31, 2025

FUJIFILM India unveils FW500, advancing biochemistry innovation in diagnostics

The FW500 is designed to meet the evolving needs of mid-sized diagnostic laboratories


EU approves Alexion’s Koselugo to treat adults with neurofibromatosis type 1 tumours
Clinical Trials | October 31, 2025

EU approves Alexion’s Koselugo to treat adults with neurofibromatosis type 1 tumours

Approval based on pivotal KOMET Phase III trial demonstrating significant tumour reduction in adults with NF1


Lupin Digital Health launches VITALYFE
Healthcare | October 31, 2025

Lupin Digital Health launches VITALYFE

AI-powered cardiometabolic wellness platform for India’s workforce


Roche’s Gazyva shows strong phase III results for treatment of idiopathic nephrotic syndrome
Clinical Trials | October 30, 2025

Roche’s Gazyva shows strong phase III results for treatment of idiopathic nephrotic syndrome

Key secondary endpoints also demonstrated statistically significant and clinically meaningful benefits with Gazyva


Quest Diagnostics’ study confirms accuracy of blood tests for Alzheimer’s disease diagnosis
R&D | October 30, 2025

Quest Diagnostics’ study confirms accuracy of blood tests for Alzheimer’s disease diagnosis

Quest Diagnostics’ blood-based test panels demonstrate confirmatory accuracy, potentially reducing the need for PET imaging


BMS unveils new data highlighting sustained efficacy and safety of Sotyktu in psoriatic arthritis and lupus
Clinical Trials | October 30, 2025

BMS unveils new data highlighting sustained efficacy and safety of Sotyktu in psoriatic arthritis and lupus

Sotyktu continues to demonstrate consistent efficacy and safety across rheumatic conditions


AskBio’s gene therapy shows promising 12-month results for heart failure
Biotech | October 29, 2025

AskBio’s gene therapy shows promising 12-month results for heart failure

Results demonstrate favorable safety profile and clinically meaningful improvements in patients with non-ischemic heart failure


FDA grants fast track status to Heidelberg Pharma’s Amanitin-based ADC candidate for multiple myeloma
Drug Approval | October 29, 2025

FDA grants fast track status to Heidelberg Pharma’s Amanitin-based ADC candidate for multiple myeloma

The Fast Track Designation was supported by nonclinical data as well as clinical results from the ongoing Phase I/IIa trial evaluating the safety and tolerability